**Gandelman 2011** Gandelman K, Malhotra B, LaBadie RR, Crownover P, Bergstrom T (2011) Analytes of Interest and Choice of Dose: Two Important Considerations in the Design of Bioequivalence Studies with Atorvastatin. *Journal of Bioequivalence & Bioavailability* *3*(4):062–068.

**Patiño-Rodríguez 2015** Patiño-Rodríguez O, Martínez-Medina RM, Torres-Roque I, Martínez-Delgado M, Mares-García AS, Escobedo-Moratilla A, Covarrubias-Pinedo A, Arzola-Paniagua A, Herrera-Torres JL, Pérez-Urizar J (2015) Absence of a significant pharmacokinetic interaction between atorvastatin and fenofibrate: a randomized, crossover, study of a fixed-dose formulation in healthy Mexican subjects. *Front Pharmacol.* *6*(4).

**Bullman 2011** Bullman J, Nicholls A, Van Landingham K, Fleck R, Vuong A, Miller J, Alexander S, Messenheimer J (2011) Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers. *Epilepsia*  *52*(7):1351–8.

**Di Spirito 2008** Di Spirito M, Morelli G, Doyle RT, Johnson J, McKenney J (2008) Effect of omega-3-acid ethyl esters on steady-state plasma pharmacokinetics of atorvastatin in healthy adults. *Expert Opin Pharmacother.* *9*(17):2939–45.

**Mazzu 2000** Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P (2008) Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. *Clin Pharmacol Ther.* *68*(4):391–400.

**Shin 2011** Shin J, Pauly DF, Pacanowski MA, Langaee T, Frye RF, Johnson JA (2011) Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. *Pharmacotherapy* *31*(10):942–50.

**Siedlik 1999** Siedlik PH, Olson SC, Yang BB, Stern RH. Erythromycin coadministration increases plasma atorvastatin concentrations (1999) *J Clin Pharmacol.* *39*(5):501–4.

**Backman 2005** Backman JT, Luurila H, Neuvonen M, Neuvonen PJ (2005) Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. *Clin Pharmacol Ther.* *78*(2):154–67.

**Whitfield 2010** Whitfield LR, Porcari AR, Alvey C, Abel R, Bullen W, Hartman D (2011) Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. *J Clin Pharmacol.* *51*(3):378–88.

**Kantola 1998** Kantola T, Kivistö KT, Neuvonen PJ (1998) Effect of itraconazole on the pharmacokinetics of atorvastatin. *Clin Pharmacol Ther.* *64*(1):58–65.

**Lau 2007** Lau YY, Huang Y, Frassetto L, Benet LZ (2007) effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. *Clin Pharmacol Ther.* *81*(2):194–204.

**Mori 2020** Mori D, Kimoto E, Rago B, Kondo Y, King-Ahmad A, Ramanathan R, Wood LS, Johnson JG, Le VH, Vourvahis M, David Rodrigues A, Muto C, Furihata K, Sugiyama Y, Kusuhara H (2020) Dose-Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs. *Clin Pharmacol Ther.* *107*(4):1004–1013.

**Takehara 2018** Takehara I, Yoshikado T, Ishigame K, Mori D, Furihata KI, Watanabe N, Ando O, Maeda K, Sugiyama Y, Kusuhara H (2018) Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers. *Pharm Res.* *35*(7):138.

**Teng 2013** Teng R, Mitchell PD, Butler KA (2013) Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. *Eur J Clin Pharmacol.* *69*(3):477–87.

**Kuepfer 2016** Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D. (2016). Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model. *CPT Pharmacometrics Syst Pharmacol*. Oct;5(10), 516-531.

**Willmann 2007** Willmann S, Höhn K, Edginton A, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W. (2007). Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. *J Pharmacokinet Pharmacodyn.* 34(3), 401-431.

**PK-Sim Ontogeny Database Version 7.3** Open Systems Pharmacology Suite Community (2018) PK-Sim® Ontogeny Database Documentation version 7.3. https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/master/PK-SimOntogenyDatabaseVersion7.3.pdf.

**Nishimura 2003** Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T (2003) Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. *Journal of the Pharmaceutical Society of Japan* *123*(5):369–75.

**Kolesnikov 2015** Kolesnikov N, Hastings E, Keays M, Melnichuk O, Tang YA, Williams E, Dylag M, Kurbatova N, Brandizi M, Burdett T, Megy K, Pilicheva E, Rustici G, Tikhonov A, Parkinson H, Petryszak R, Sarkans U, Brazma A (2015) ArrayExpress update—simplifying data submissions. *Nucleic Acids Research* *43*(D1):D1113–D1116.

**Nishimura 2005** Nishimura M, Naito S (2005) Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. *Drug metabolism and pharmacokinetics* *20*(6):452–77.

**Zhang 2015** Zhang T (2015) Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites. *Eur J Pharm Sci.* *77*:216–29.

**Morse 2019** Morse BL, Alberts JJ, Posada MM, Rehmel J, Kolur A, Tham LS, Loghin C, Hillgren KM, Hall SD, Dickinson GL (2019) Physiologically-Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid-to-Lactone Conversion. *CPT Pharmacometrics Syst Pharmacol.* 2019 *8*(9):664–675.

**Duan 2017** Duan P, Zhao P, Zhang L (2017) Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs). *Eur J Drug Metab Pharmacokinet.* *42*(4):689–705.

**Jacobsen 2000** Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, Christians U (2000) Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. *Drug Metab Dispos.* *28*(11):1369–78.

**Deng 2021** Deng F, Tuomi SK, Neuvonen M, Hirvensalo P, Kulju S, Wenzel C, Oswald S, Filppula AM, Niemi M (2021) Comparative Hepatic and Intestinal Efflux Transport of Statins. *Drug Metab Dispos.* *49*(9):750–759.

**Vildhede 2014** Vildhede A, Karlgren M, Svedberg EK, Wisniewski JR, Lai Y, Norén A, Artursson P (2014) Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions. *Drug Metab Dispos.* *42*(7):1210–8.

**Hanke 2018** Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, Lehr T (2018) PBPK models for CYP3A4 and P-gp DDI prediction: A modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin. *CPT: Pharmacometrics & Systems Pharmacology* *7*(10):647–659.

**Park 2022** Park J-W, Kim J-M, Lee H-Y, Noh J, Kim K-A, Park J-Y (2022) CYP3A5*3 and SLCO1B1 c.521T>C Polymorphisms Influence the Pharmacokinetics of Atorvastatin and 2-Hydroxy Atorvastatin. *Pharmaceutics* *14*(7):1491.

**Park 2008** Park JE, Kim KB, Bae SK, Moon BS, Liu KH, Shin JG (2008) Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. *Xenobiotica* *38*(9):1240-1251.

**Pfizer 2019** Pfizer (2019) https://labeling.pfizer.com/ShowLabeling.aspx?id=587. Accessed on 2025-02-11.